S Schulman

Summary

Affiliation: Karolinska Hospital
Country: Sweden

Publications

  1. ncbi request reprint Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Semin Thromb Hemost 29:33-6. 2003
  2. ncbi request reprint Continuous infusion
    S Schulman
    Department of Haematology, Coagulation Unit, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 9:368-75. 2003
  3. ncbi request reprint [There is evidence for prolonged low-intensity warfarin therapy after venous thrombosis]
    Sam Schulman
    Centrum för hematologi, Karolinska sjukhuset, Stockholm
    Lakartidningen 100:2118-21. 2003
  4. ncbi request reprint Unresolved issues in anticoagulant therapy
    S Schulman
    Coagulation Unit, Division of Hematology, Department of Medicine, Karolinska Hospital, Sweden
    J Thromb Haemost 1:1464-70. 2003
  5. ncbi request reprint Pregnancy, heparin and osteoporosis
    Sam Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Thromb Haemost 87:180-1. 2002
  6. ncbi request reprint Inhibition of warfarin activity by ribavirin
    Sam Schulman
    Coagulation Unit, Division of Hematology, Department of Medicine, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Ann Pharmacother 36:72-4. 2002
  7. ncbi request reprint Clinical practice. Care of patients receiving long-term anticoagulant therapy
    Sam Schulman
    Coagulation Unit, Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 349:675-83. 2003
  8. ncbi request reprint Duration of anticoagulants in acute or recurrent venous thromboembolism
    S Schulman
    Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Curr Opin Pulm Med 6:321-5. 2000
  9. ncbi request reprint Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial
    S Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 342:1953-8. 2000
  10. ncbi request reprint [Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer]
    Sam Schulman
    Centrum för hematologi, Karolinska Universitetssjukhuset Solna
    Lakartidningen 101:1712-5. 2004

Collaborators

Detail Information

Publications65

  1. ncbi request reprint Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Semin Thromb Hemost 29:33-6. 2003
    ..Conversely, the differentiated inhibition of the coagulation protease on vascular receptors may play a greater role for effects that are not traditionally considered as part of hemostasis...
  2. ncbi request reprint Continuous infusion
    S Schulman
    Department of Haematology, Coagulation Unit, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 9:368-75. 2003
    ..Future studies should address the question of minimum steady-state levels required for haemostasis, comparisons with bolus injection using a randomized design and investigate the risk of inhibitor formation...
  3. ncbi request reprint [There is evidence for prolonged low-intensity warfarin therapy after venous thrombosis]
    Sam Schulman
    Centrum för hematologi, Karolinska sjukhuset, Stockholm
    Lakartidningen 100:2118-21. 2003
  4. ncbi request reprint Unresolved issues in anticoagulant therapy
    S Schulman
    Coagulation Unit, Division of Hematology, Department of Medicine, Karolinska Hospital, Sweden
    J Thromb Haemost 1:1464-70. 2003
    ..0-2.5 in combination with low-dose aspirin, but is it really cost-effective? Finally, many controversies exist regarding anticoagulation during pregnancy...
  5. ncbi request reprint Pregnancy, heparin and osteoporosis
    Sam Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Thromb Haemost 87:180-1. 2002
  6. ncbi request reprint Inhibition of warfarin activity by ribavirin
    Sam Schulman
    Coagulation Unit, Division of Hematology, Department of Medicine, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Ann Pharmacother 36:72-4. 2002
    ..To report a case of inhibition of the effect of warfarin during treatment with ribavirin...
  7. ncbi request reprint Clinical practice. Care of patients receiving long-term anticoagulant therapy
    Sam Schulman
    Coagulation Unit, Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 349:675-83. 2003
  8. ncbi request reprint Duration of anticoagulants in acute or recurrent venous thromboembolism
    S Schulman
    Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Curr Opin Pulm Med 6:321-5. 2000
    ..Many studies on the influence of biochemical factors in the risk of recurrence have also been published recently. This review should be helpful in-the individual decision on how to tailor the duration of anticoagulation...
  9. ncbi request reprint Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial
    S Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 342:1953-8. 2000
    ..The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial...
  10. ncbi request reprint [Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer]
    Sam Schulman
    Centrum för hematologi, Karolinska Universitetssjukhuset Solna
    Lakartidningen 101:1712-5. 2004
  11. ncbi request reprint Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 349:1713-21. 2003
    ..For many patients with venous thromboembolism, secondary prevention with vitamin K antagonists is not extended beyond six months, since the risk of recurrence may be outweighed by the risk of major bleeding...
  12. ncbi request reprint Novel anticoagulant agents: introduction
    S Schulman
    Department of Medicine, Coagulation Unit, Division of Hematology, Karolinska Hospital, Stockholm, Sweden
    J Intern Med 254:308-12. 2003
    ..This introduction attempts to explain the different mechanisms of action on a broad scale, and also includes a brief look at effects on inflammation and cancer...
  13. ncbi request reprint Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Thromb Haemost 89:741-6. 2003
    ..We conclude that screening and eradication therapy for infection with H. pylori in patients with congenital bleeding disorders is an effective and economic strategy...
  14. ncbi request reprint Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months
    S Schulman
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 4:734-42. 2006
    ..The influence of the duration of anticoagulant therapy after venous thromboembolism (VTE) on the long-term morbidity and mortality is unclear...
  15. ncbi request reprint A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
    H Eriksson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Thromb Haemost 1:41-7. 2003
    ..Oral ximelagatran appears to be a promising alternative to current anticoagulant therapy to limit the progression of acute DVT, and it seems to possess a wide therapeutic window...
  16. ncbi request reprint Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings
    S Schulman
    Department of Haematology and Infectious Disease, Karolinska Hospital, Stockholm, Sweden
    J Intern Med 245:399-403. 1999
    ..The optimal treatment regimen is individualized, taking into account a variety of risk factors, and re-evaluated regularly in case of prolonged therapy...
  17. doi request reprint Low PAI-1 activity in relation to inflammatory parameters, insulin profile and body mass index
    A Agren
    Department of Medicine, Karolinska Institute, Stockholm, Sweden
    J Intern Med 264:586-92. 2008
    ..The purpose of this study was to investigate if patients with low PAI-1 activity have a lack of inflammatory response or a low insulin level...
  18. doi request reprint Validation of a composite score for clinical severity of hemophilia
    S Schulman
    Coagulation Unit, Department of Hematology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 6:1113-21. 2008
    ..Evaluation of modulators of the phenotypic expression of hemophilia may benefit from a scoring system that reflects several aspects of the clinical severity instead of only one dimension...
  19. ncbi request reprint A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders
    S Schulman
    Department of Hematology, Stockholm, Sweden
    Haemophilia 8:129-35. 2002
    ..For other genotypes, the decision regarding duration of therapy has to be based on the tolerance of the individual patient together with experiences from other studies...
  20. ncbi request reprint Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate
    A Agren
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, S 171 76 Stockholm, Sweden
    Thromb Res 119:715-21. 2007
    ..The aim of this study was to investigate prospectively whether low PAI-1 activity increases the risk for perioperative bleeding in patients undergoing transurethral resection of prostate, an organ with high fibrinolytic activity...
  21. ncbi request reprint Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery
    S Schulman
    Coagulation Unit, Department of Haematology, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 5:96-100. 1999
    ..Thus, continuous infusion with this highly purified factor IX concentrate with improved viral safety is effective for surgery in haemophilia B...
  22. doi request reprint The plasma concentration of activated protein C appears normal in patients with haemophilia
    S Schulman
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haemophilia 15:566-70. 2009
    ..Patients with haemophilia appear to generate normal concentrations of APC during basal conditions. APC does not seem to be an important modulator of the phenotypic expression of haemophilia...
  23. ncbi request reprint Experiences with continuous infusion of recombinant activated factor VII
    S Schulman
    Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 9:S97-101. 1998
    ..The question of optimal monitoring needs further attention. Haemorrhagic complications were significantly less frequent when treatment was combined with the antifibrinolytic tranexamic acid...
  24. ncbi request reprint Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness
    S Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Semin Thromb Hemost 26:421-4. 2000
    ..The only indications discussed here are hemophilia A or B with inhibitors or acquired hemophilia. Different recommendations may apply for other indications...
  25. ncbi request reprint Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A
    J Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 7:557-60. 2001
    ..In this paper we use new nomenclature for TAFI, and we believe that this recommended terminology for different forms of TAFI can simplify further standardization in TAFI investigation...
  26. ncbi request reprint Optimal duration of oral anticoagulant therapy in venous thromboembolism
    S Schulman
    Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Thromb Haemost 78:693-8. 1997
    ..The ideal solutions will perhaps only be achieved when we have learned how to combine the optimal duration with a time-adjusted decrease in oral anticoagulation...
  27. ncbi request reprint Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    J P Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska University Hospital, Stockholm, Sweden
    Scand J Clin Lab Invest 64:745-51. 2004
    ..The relationship between the TAFI activation pathway and bleeding complications associated with hemophilia A, hemophilia B and VWD requires further investigation...
  28. ncbi request reprint Hypercoagulability preceding cancer. Are anticoagulants also antineoplastic?
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:581-3. 2005
  29. ncbi request reprint Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group
    S Schulman
    Coagulation Unit, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 4:564-7. 1998
    ..The experience is reviewed here and compared with data from the conventional bolus dose regimen...
  30. ncbi request reprint The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group
    S Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Wien Med Wochenschr 149:66-9. 1999
    ..In order to find the optimal balance of anticoagulation, avoiding recurrent events as well as major hemorrhage, it is important to know the impact of different risk factors over time...
  31. ncbi request reprint Haemostatic and replacement therapy in von Willebrand disease
    S Schulman
    Coagulation Unit, Department of Haematology and Infectious Disease, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 5:57-9. 1999
    ..The choice depends on the type of haemorrhage, the severity of the disease, presence of inhibitors, availability and cost. Some of these aspects are reviewed here...
  32. ncbi request reprint An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency
    S Schulman
    Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haemophilia 12:223-7. 2006
    ..A bolus dose of 20 microg kg(-1) and thereafter maintenance of the FVII activity at approximately 3 IU mL(-1) appears effective and safe...
  33. ncbi request reprint Minimizing factor requirements for surgery without increased risk
    S Schulman
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, S 171 76 Stockholm, Sweden
    Haemophilia 10:35-40. 2004
    ..In addition, we review the possibilities to reduce the amount of factor concentrate by performing a combination of orthopaedic procedures and using local haemostatic agents or antifibrinolytic agents...
  34. ncbi request reprint Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:692-4. 2005
    ..The intention is to also seek approval of this definition from the regulatory authorities...
  35. ncbi request reprint Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis
    A Agren
    Department of Hematology, Coagulation Unit, King Gustaf V Research Institute, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 4:201-8. 2006
    ..Prospective studies of the epidemiology and clinical significance of low plasminogen activator inhibitor type 1 (PAI-1) activity are lacking...
  36. ncbi request reprint Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome--normalization of bleeding time after aortic valve replacement
    M Olsson
    Department of Cardiology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
    J Intern Med 252:516-23. 2002
    ..Despite several studies attempting to determine the prevalence and to discuss the aetiology, there are still many unanswered questions...
  37. ncbi request reprint The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism
    James D Douketis
    McMaster University, Hamilton, Ontario, Canada
    Ann Intern Med 147:766-74. 2007
    ..The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment...
  38. ncbi request reprint NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study
    Dag Nilsson
    Medical Neuroscience, AstraZeneca R and D, Sodertalje, SE 151 85, Sweden
    J Clin Pharmacol 47:264-72. 2007
    ..At a mean unbound plasma concentration (Cu(ss)) of 335 micromol/L, NXY-059 was well tolerated, with no major safety concerns identified. In conclusion, NXY-059 does not appear to affect primary hemostasis...
  39. ncbi request reprint Anticoagulants and their reversal
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Transfus Med Rev 21:37-48. 2007
    ..Additional options that may become available in the future are also discussed briefly...
  40. ncbi request reprint New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 96:258-66. 2006
    ..The conclusions drawn should help clinicians make balanced decisions on the optimal duration of anticoagulation after an episode of VTE...
  41. doi request reprint Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations
    Andreas Tiede
    Hannover Medical School, Dept of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Germany
    Thromb Haemost 99:616-22. 2008
    ..In conclusion, this study suggests that antithrombin alfa is a safe and effective alternative to human plasma-derived AT for treating hereditary AT deficiency patients at high risk for thromboembolic events...
  42. ncbi request reprint Thromboprophylaxis in medical patients--why not for all?
    Sam Schulman
    Dept of Medicine, McMaster University, Hamilton, Canada
    Pathophysiol Haemost Thromb 35:141-5. 2006
    ..The agents are generally safe, with only a small increase of major bleeding, less with LMWH than with unfractionated heparin. The challenge is still to direct the efforts to the most appropriate patients...
  43. doi request reprint Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Sam Schulman
    McMaster Clinics, HHS General Hospital, 237 Barton Street E, Hamilton, Ontario, Canada
    Chest 133:257S-298S. 2008
    ..Thrombolytic therapy increases the risk of major bleeding 1.5-fold to threefold in patients with acute venous thromboembolism, ischemic stroke, or ST-elevation myocardial infarction...
  44. ncbi request reprint Acquired hemophilia masked by warfarin therapy: report on two cases
    Bertil Uggla
    Department of Medicine, Orebro University Hospital, Orebro, Sweden
    Blood Coagul Fibrinolysis 14:769-72. 2003
    ..The special problems of keeping the balance between thrombosis and bleeding in this group of patients with need of anticoagulation due to mechanical heart valves or other thrombogenic factors are discussed...
  45. ncbi request reprint The onerous task of comparing treatments in inhibitor patients
    Sam Schulman
    Thromb Haemost 98:710-2. 2007
  46. ncbi request reprint Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism
    Karin Wåhlander
    AstraZeneca Research and Development Mölndal, Molndal, Sweden
    Br J Haematol 133:68-77. 2006
    ..There was no clear evidence for a higher risk of recurrent VTE or bleeding across subgroups according to the potential prothrombotic factors analysed in this study...
  47. ncbi request reprint Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Mark N Levine
    Henderson Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3
    Chest 126:287S-310S. 2004
    ..In terms of treatment decision making for anticoagulant therapy, bleeding risk cannot be considered alone, ie, the potential decrease in thromboembolism must be balanced against the potential increased bleeding risk...
  48. ncbi request reprint Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism
    Per Svensson
    Division of Emergency Medicine, Dept of Medicine, Karolinska Hospital, Stockholm, Sweden
    Hematol J 3:311-4. 2002
    ..In patients at a high risk for recurrence of VTE an initial period of regular intensity anticoagulation, followed by a low-intensity regimen, may provide effective and safe secondary prophylaxis...
  49. ncbi request reprint The role of ximelagatran in the treatment of venous thromboembolism
    Sam Schulman
    Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Pathophysiol Haemost Thromb 34:18-24. 2005
    ....
  50. ncbi request reprint Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis
    Marie Cullberg
    Clinical Pharmacology and Clinical Cardiovascular, AstraZeneca R and D Molndal, Molndal, Sweden
    Clin Pharmacol Ther 77:279-90. 2005
    ....
  51. ncbi request reprint Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis
    Simon McRae
    Department of Haematology and Oncology, Queen Elizabeth Hospital, Woodville, Australia
    Lancet 368:371-8. 2006
    ..We did a meta-analysis to assess from available evidence whether men and women have the same risk of recurrent venous thromboembolism after stopping anticoagulant treatment...
  52. ncbi request reprint A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran
    Stefan C Carlsson
    AstraZeneca R and D Molndal, Molndal, Sweden
    Semin Vasc Med 5:259-65. 2005
    ....
  53. ncbi request reprint Ximelagatran in the clinic: practical management of patients
    Sam Schulman
    Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
    Semin Vasc Med 5:301-7. 2005
    ..The evidence for established management strategies is reviewed and, finally, practical handling of the case is considered...
  54. ncbi request reprint Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran
    Henry Eriksson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Thromb Haemost 94:522-7. 2005
    ..Long-term use of oral ximelagatran, without coagulation monitoring or dose adjustment, should be feasible and well tolerated in a wide cross-section of patients for the secondary prevention of VTE...
  55. ncbi request reprint Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Canada
    Thromb Haemost 94:820-4. 2005
    ..36, 1.93; P = 0.7). This complementary follow-up analysis confirms the benefit of oral ximelagatran 24 mg twice daily, administered without coagulation monitoring or dose adjustment, for the long-term secondary prevention of VTE...
  56. ncbi request reprint Optimal reversal of vitamin K antagonists
    Sam Schulman
    Thromb Res 119:15-6. 2007
  57. ncbi request reprint Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects
    Johan Wemer
    AstraZeneca R and D, Sodertalje, Sweden
    Curr Med Res Opin 22:1813-23. 2006
    ..This study evaluated the safety, tolerability and pharmacokinetics of NXY-059 in the unbound steady-state plasma concentration (Cu(ss)) exposure range of 50-300 micromol/L in healthy young and elderly subjects...
  58. ncbi request reprint Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII
    Sam Schulman
    Coagulation Unit, Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Thromb Haemost 94:1177-80. 2005
    ..This mode of substitution was therefore safe, effective and well tolerated...
  59. ncbi request reprint Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
    Astrid K N Iversen
    Department of Medical Microbiology and Immunology, Arhus University School of Medicine, Denmark
    J Infect Dis 187:215-25. 2003
    ..Sequence comparisons indicate that X4 virus can be selected in vivo due to either absence of CCR5 receptors or relative increase of CXCR4 receptors...
  60. ncbi request reprint [Bleeding time--only in special cases. The method is of little value as a general screening analysis]
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Kanada
    Lakartidningen 105:1268. 2008
  61. doi request reprint Current strategies in prophylaxis and treatment of venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Ann Med 40:352-9. 2008
    ..Although new, orally available anticoagulants without need for monitoring or dose adjustments have been in clinical trials for a decade, none is approved yet, and will not be discussed in this review...
  62. ncbi request reprint Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?
    Johanna S Ungerstedt
    Blood 99:2271-2. 2002
  63. ncbi request reprint Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy
    Kristina Koppel
    Venhälsan Gay Men s Health Clinic, Karolinska Institute, Söder Hospital Stockholm, 118 83 Stockholm, Sweden
    J Acquir Immune Defic Syndr 29:441-9. 2002
    ..001). These findings suggest that patients receiving PI-containing HAART have decreased fibrinolysis and increased coagulability, which may thus represent additional risk factors for cardiovascular disease in this patient group...
  64. ncbi request reprint Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity
    Anna Agren
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 18:657-60. 2007
    ..0 U/ml. The coagulation activity under normal conditions, as measured by D-dimer, did not differ between the two patient subsets. The results support our previous definition of low PAI-1 as activity below 1.0 U/ml...
  65. ncbi request reprint Recombinant FVIIa in children with liver disease
    Maria Pettersson
    Department of Paediatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm S 141 86, Sweden
    Thromb Res 116:185-97. 2005
    ..The aim of this study was to investigate the clinical and biochemical effects of recombinant activated factor VII (rFVIIa) in the treatment of bleeding in children with liver disease...